Drug Approval | November 02, 2024
USFDA inspection of Shilpa Medicare Unit VI at Bengaluru
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
The new facility uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Subscribe To Our Newsletter & Stay Updated
